Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 13/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.65 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20893167 | 0.94 | SIRT1 (0.88) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2624513 | 0.93 | SIRT1 (0.87) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2624433 | 0.92 | SIRT1 (0.85) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL14654576 | 0.92 | SIRT1 (0.84) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2624691 | 0.91 | SIRT1 (0.83) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL10245951 | 0.90 | SIRT1 (0.81) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2740381 | 0.89 | SIRT1 (0.80) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2740426 | 0.88 | SIRT1 (1.00) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2740431 | 0.87 | SIRT1 (0.82) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2624781 | 0.87 | SIRT1 (1.00) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032581-A1 | COMPOSITIONS AND ARTICLES COMPRISING AN ADNF POLYPEPTIDE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-01-30 | — | — | US | claimed |
| US-20240335473-A1 | USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1ALPHA) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-10-10 | — | — | US | claimed |
| US-20240156973-A1 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2024-05-16 | — | — | US | claimed |
| EP-4340890-A1 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | Purdue Research Foundation (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4313116-A1 | COMPOSITIONS AND ARTICLES COMPRISING AN ADNF POLYPEPTIDE | Ramot at Tel-Aviv University Ltd. (IL) | 2024-02-07 | — | — | EP | claimed |
| WO-2022201166-A1 | COMPOSITIONS AND ARTICLES COMPRISING AN ADNF POLYPEPTIDE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-09-29 | — | — | WO | claimed |
| WO-2022182920-A1 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2022-09-01 | — | — | WO | claimed |
| CN-114762732-A | Controlled release microspheres and anti-aging application thereof | 梦芊科技知识产权有限公司 | 2022-07-19 | — | — | CN | claimed |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250346550-A1 | METHODS OF MODULATING ENDONUCLEASE G USING RESVERATROL AND ITS DERIVATIVES | UNIV COLORADO REGENTS (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4647083-A2 | COMPOSITIONS FOR FACILITATING MEMBRANE FUSION AND USES THEREOF | Flagship Pioneering Innovations V, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-3397260-B1 | SUB-MITOCHONDRIAL PARTICLES FOR USE IN TREATING METABOLIC CONDITIONS | SANA BIOTECHNOLOGY INC (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4620519-A2 | METHODS AND COMPOSITIONS RELATING TO CHONDRISOMES FROM BLOOD PRODUCTS | Sana Biotechnology, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346550-A1 | METHODS OF MODULATING ENDONUCLEASE G USING RESVERATROL AND ITS DERIVATIVES | ENDOD1, FEN1, RNASE1 | SIRT1 445/4885CHRM2 4683/4885ADRA2A 4211/4885 |
| US-20240335473-A1 | USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1ALPHA) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) | PPARD, PPARA, PPARG | SIRT1 36/4885CHRM2 2598/4885ADRA2A 472/4885 |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | SIRT1 2/4885CHRM2 4024/4885ADRA2A 1990/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | SIRT1 4753/4885CHRM2 1322/4885ADRA2A 4613/4885 |
| US-20240156973-A1 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | SOST, BMP2, BMP6 | SIRT1 4605/4885CHRM2 4218/4885ADRA2A 928/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885CHRM2 4790/4885ADRA2A 3791/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | SIRT1 1536/4885CHRM2 1562/4885ADRA2A 472/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | SIRT1 2/4885CHRM2 4038/4885ADRA2A 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.